Table 3.

Radionuclides used in active clinical trials for AML.

Radionuclide	T ½	Emission	Emax (keV)	Range (µm)
β-Emitting Radionuclides (LET = 0.1–1.0 keV/µm)
Iodine-131	8.02 days	β and γ	610/362	2300
Yttrium-90	2.67 days	β	2250	11,300
α-Emitting Radionuclides (LET = 50–230 keV/µm)
Astatine-211	7.2 h	α and X	5870 and 7450/ 77–92	80
Actinium-225	9.92 days	4α, 2β and γ	6000–8000/ 198–659/218–444	90
Bismuth-213	45.59 min	α and γ	8400/440	17